Header Logo
Keywords
Last Name
Institution

Matthias Schnell

TitleProfessor & Chair JMC
InstitutionThomas Jefferson University
DepartmentChair SKMC
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    R21AI044340     (SCHNELL, MATTHIAS JOHANNES)Sep 30, 1998 - Sep 29, 2000
    NIH/NIAID
    RABIES VIRUS BASED VECTORS AS AN HIV1 VACCINE
    Role: Principal Investigator

    R21AI049153     (SCHNELL, MATTHIAS JOHANNES)Mar 15, 2001 - May 31, 2005
    NIH/NIAID
    Rabies Virus-Based Vectors as an HIV -1 Vaccine
    Role: Principal Investigator

    R01AI049153     (SCHNELL, MATTHIAS JOHANNES)Mar 15, 2001 - Feb 28, 2010
    NIH/NIAID
    Rabies Virus-Based Vectors as an HIV-1 Vaccine
    Role: Principal Investigator

    R21AI051170     (SCHNELL, MATTHIAS JOHANNES)Jul 1, 2002 - Jun 30, 2005
    NIH/NIAID
    Prime/Boost Immunization against HIV-1 by Viral Vectors
    Role: Principal Investigator

    R21AI062807     (SCHNELL, MATTHIAS JOHANNES)Jul 5, 2005 - Jun 30, 2008
    NIH/NIAID
    Killed Rhabdoviruses as Novel Anthrax Vaccines
    Role: Principal Investigator

    R01MH074375     (SCHNELL, MATTHIAS JOHANNES)Sep 15, 2005 - May 31, 2009
    NIH/NIMH
    Astrocytes and Restricted HIV-1 Replication
    Role: Principal Investigator

    R41AI063822     (SCHNELL, MATTHIAS JOHANNES)Apr 15, 2006 - Mar 31, 2009
    NIH/NIAID
    A novel rhabdovirus-based anthrax vaccine
    Role: Principal Investigator

    R41AI073064     (SCHNELL, MATTHIAS JOHANNES)Apr 1, 2008 - Sep 30, 2010
    NIH/NIAID
    A novel vaccine: botulinum neurotoxin subunit on a viral carrier.
    Role: Principal Investigator

    R21AI081388     (SCHNELL, MATTHIAS JOHANNES)Jun 1, 2009 - May 31, 2012
    NIH/NIAID
    Bat rabies virus in its natural host
    Role: Principal Investigator

    P01AI082325     (SCHNELL, MATTHIAS JOHANNES)Sep 1, 2009 - Aug 31, 2012
    NIH/NIAID
    Functional Analysis of NSV-based HIV vectors
    Role: Principal Investigator

    R21NS074006     (SCHNELL, MATTHIAS JOHANNES)Jul 1, 2011 - Jun 30, 2014
    NIH/NINDS
    Fate of neurons following immune-mediated viral clearance
    Role: Principal Investigator

    R42AI073064     (SCHNELL, MATTHIAS JOHANNES)Jun 21, 2012 - May 31, 2015
    NIH/NIAID
    A novel vaccine: botulinum neurotoxin subunit on a viral carrier.
    Role: Principal Investigator

    R01AI105204     (SCHNELL, MATTHIAS JOHANNES)Feb 1, 2013 - Jan 31, 2018
    NIH/NIAID
    Preclinical characterization of a multivalent killed Filovirus/Rabies vaccine
    Role: Principal Investigator

    R01AI127823     (SCHNELL, MATTHIAS JOHANNES)Nov 15, 2016 - Oct 31, 2019
    NIH/NIAID
    Drug discovery against lyssaviruses by high thoughput screening
    Role: Principal Investigator

    R01AI123272     (SCHNELL, MATTHIAS JOHANNES)Nov 22, 2016 - Oct 31, 2021
    NIH/NIAID
    Development of a single-dose rabies virus vaccine
    Role: Principal Investigator

    R21AI128175     (SCHNELL, MATTHIAS JOHANNES)Dec 1, 2016 - Nov 30, 2018
    NIH/NIAID
    Toward an Pan-lyssavirus vaccine
    Role: Principal Investigator

    T32AI134646     (SIGAL, LUIS J)Sep 1, 2018 - Aug 31, 2023
    NIH/NIAID
    Training grant on Vaccines and Immunotherapies for Infectious Diseases and Cancer
    Role: Co-Principal Investigator

    R01AI149795     (SCHNELL, MATTHIAS JOHANNES)Jan 1, 2020 - Dec 31, 2024
    NIH/NIAID
    Pan-lyssavirus therapeutics and mechanisms of protection against lyssaviruses
    Role: Principal Investigator

    R21AI158044     (SCHNELL, MATTHIAS JOHANNES)Jul 16, 2020 - Jun 30, 2022
    NIH/NIAID
    Toward a protective Covid-19 vaccine utilizing an established vector platform
    Role: Principal Investigator

    R01AI154542     (PAL, UTPAL)Jul 20, 2020 - Jun 30, 2025
    NIH/NIAID
    Multivalent Tick-Microbe targeted Lyme disease vaccines
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Kurup D, Fisher CR, Scher G, Yankowski C, Testa A, Keshwara R, Abreu-Mota T, Lambert R, Ferguson M, Rinaldi W, Ruiz L, Wirblich C, Schnell MJ. Tetravalent rabies-vectored Filovirus and Lassa fever vaccine induces long-term immunity in nonhuman primates. J Infect Dis. 2021 Jan 09. PMID: 33421072.
      View in: PubMed
    2. Scher G, Schnell MJ. Rhabdoviruses as vectors for vaccines and therapeutics. Curr Opin Virol. 2020 Oct; 44:169-182. PMID: 33130500.
      View in: PubMed
    3. Kurup D, Wirblich C, Ramage H, Schnell MJ. Rabies virus-based COVID-19 vaccine CORAVAX™ induces high levels of neutralizing antibodies against SARS-CoV-2. NPJ Vaccines. 2020; 5:98. PMID: 33088593.
      View in: PubMed
    4. Fisher CR, Lowe DE, Smith TG, Yang Y, Hutson CL, Wirblich C, Cingolani G, Schnell MJ. Lyssavirus Vaccine with a Chimeric Glycoprotein Protects across Phylogroups. Cell Rep. 2020 Jul 21; 32(3):107920. PMID: 32697993.
      View in: PubMed
    5. Du Pont V, Wirblich C, Yoon JJ, Cox RM, Schnell MJ, Plemper RK. Identification and Characterization of a Small-Molecule Rabies Virus Entry Inhibitor. J Virol. 2020 Apr 22. PMID: 32321812.
      View in: PubMed
    6. Kurup D, Fisher CR, Smith TG, Abreu-Mota T, Yang Y, Jackson FR, Gallardo-Romero N, Franka R, Bronshtein V, Schnell MJ. Inactivated Rabies Virus-Based Ebola Vaccine Preserved by Vaporization Is Heat-Stable and Immunogenic Against Ebola and Protects Against Rabies Challenge. J Infect Dis. 2019 Aug 03. PMID: 31374568.
      View in: PubMed
    7. Keshwara R, Shiels T, Postnikova E, Kurup D, Wirblich C, Johnson RF, Schnell MJ. Erratum: Publisher Correction: Rabies-based vaccine induces potent immune responses against Nipah virus. NPJ Vaccines. 2019; 4:18. PMID: 31098303.
      View in: PubMed
    8. Keshwara R, Shiels T, Postnikova E, Kurup D, Wirblich C, Johnson RF, Schnell MJ. Rabies-based vaccine induces potent immune responses against Nipah virus. NPJ Vaccines. 2019; 4:15. PMID: 31016033.
      View in: PubMed
    9. Taylor E, Banyard AC, Bourhy H, Cliquet F, Ertl H, Fehlner-Gardiner C, Horton DL, Mani RS, Müller T, Rupprecht CE, Schnell MJ, Del Rio Vilas V, Fooks AR. Avoiding preventable deaths: The scourge of counterfeit rabies vaccines. Vaccine. 2019 Mar 25. PMID: 30922698.
      View in: PubMed
    10. Qin S, Volokhov D, Rodionova E, Wirblich C, Schnell MJ, Chizhikov V, Dabrazhynetskaya A. A new recombinant rabies virus expressing a green fluorescent protein: A novel and fast approach to quantify virus neutralizing antibodies. Biologicals. 2019 Mar 18. PMID: 30898479.
      View in: PubMed
    11. Du Pont V, Plemper RK, Schnell MJ. Status of antiviral therapeutics against rabies virus and related emerging lyssaviruses. Curr Opin Virol. 2019 Feb 09; 35:1-13. PMID: 30753961.
      View in: PubMed
    12. Keshwara R, Hagen KR, Abreu-Mota T, Papaneri AB, Liu D, Wirblich C, Johnson RF, Schnell MJ. A Recombinant Rabies Virus Expressing the Marburg Virus Glycoprotein is Dependent Upon ADCC for Protection Against Marburg Virus Disease in a Murine Model. J Virol. 2018 Dec 19. PMID: 30567978.
      View in: PubMed
    13. Liu DX, Perry DL, Evans DeWald L, Cai Y, Hagen KR, Cooper TK, Huzella LM, Hart R, Bonilla A, Bernbaum JG, Janosko KB, Adams R, Johnson RF, Kuhn JH, Schnell MJ, Crozier I, Jahrling PB, de la Torre JC. Persistence of Lassa Virus Associated With Severe Systemic Arteritis in Convalescing Guinea Pigs (Cavia porcellus). J Infect Dis. 2018 Dec 05. PMID: 30517671.
      View in: PubMed
    14. Abreu-Mota T, Hagen KR, Cooper K, Jahrling PB, Tan G, Wirblich C, Johnson RF, Schnell MJ. Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever. Nat Commun. 2018 Oct 11; 9(1):4223. PMID: 30310067.
      View in: PubMed
    15. MacGibeny MA, Koyuncu OO, Wirblich C, Schnell MJ, Enquist LW. Retrograde axonal transport of rabies virus is unaffected by interferon treatment but blocked by emetine locally in axons. PLoS Pathog. 2018 Jul; 14(7):e1007188. PMID: 30028873.
      View in: PubMed
    16. Fisher CR, Streicker DG, Schnell MJ. The spread and evolution of rabies virus: conquering new frontiers. Nat Rev Microbiol. 2018 Apr; 16(4):241-255. PMID: 29479072.
      View in: PubMed
    17. Perry DL, Huzella LM, Bernbaum JG, Holbrook MR, Jahrling PB, Hagen KR, Schnell MJ, Johnson RF. Ebola Virus Localization in the Macaque Reproductive Tract during Acute Ebola Virus Disease. Am J Pathol. 2018 Mar; 188(3):550-558. PMID: 29429544.
      View in: PubMed
    18. Davis BM, Fensterl V, Lawrence TM, Hudacek AW, Sen GC, Schnell MJ. Ifit2 is a Restriction Factor in Rabies Virus Pathogenicity. J Virol. 2017 Jun 21. PMID: 28637751.
      View in: PubMed
    19. Schnell MJ. Progress in Ebola Virus Vaccine Development. J Infect Dis. 2017 Jun 15; 215(12):1775-1776. PMID: 28431160.
      View in: PubMed
    20. da Fontoura Budaszewski R, Hudacek A, Sawatsky B, Krämer B, Yin X, Schnell MJ, von Messling V. Inactivated Recombinant Rabies Viruses Displaying Canine Distemper Virus Glycoproteins Induce Protective Immunity against Both Pathogens. J Virol. 2017 Apr 15; 91(8). PMID: 28148801.
      View in: PubMed
    21. Walsh PD, Kurup D, Hasselschwert DL, Wirblich C, Goetzmann JE, Schnell MJ. The Final (Oral Ebola) Vaccine Trial on Captive Chimpanzees? Sci Rep. 2017 Mar 09; 7:43339. PMID: 28277549.
      View in: PubMed
    22. Miller KD, Schnell MJ, Rall GF. Keeping it in check: chronic viral infection and antiviral immunity in the brain. Nat Rev Neurosci. 2016 Dec; 17(12):766-776. PMID: 27811921.
      View in: PubMed
    23. Wirblich C, Coleman CM, Kurup D, Abraham TS, Bernbaum JG, Jahrling PB, Hensley LE, Johnson RF, Frieman MB, Schnell MJ. One-Health: A Safe, Efficient Dual-use Vaccine for Humans and Animals against MERS-CoV and Rabies Virus. J Virol. 2016 Nov 2. PMID: 27807241.
      View in: PubMed
    24. Keshwara R, Johnson RF, Schnell MJ. Toward an Effective Ebola Virus Vaccine. Annu Rev Med. 2017 Jan 14; 68:371-386. PMID: 27686015.
      View in: PubMed
    25. Johnson RF, Kurup D, Hagen KR, Fisher C, Keshwara R, Papaneri A, Perry DL, Cooper K, Jahrling PB, Wang JT, Ter Meulen J, Wirblich C, Schnell MJ. An Inactivated Rabies Virus-Based Ebola Vaccine, FILORAB1, Adjuvanted With Glucopyranosyl Lipid A in Stable Emulsion Confers Complete Protection in Nonhuman Primate Challenge Models. J Infect Dis. 2016 Oct 15; 214(suppl 3):S342-S354. PMID: 27456709.
      View in: PubMed
    26. Reardon TR, Murray AJ, Turi GF, Wirblich C, Croce KR, Schnell MJ, Jessell TM, Losonczy A. Rabies Virus CVS-N2c(?G) Strain Enhances Retrograde Synaptic Transfer and Neuronal Viability. Neuron. 2016 Feb 17; 89(4):711-24. PMID: 26804990.
      View in: PubMed
    27. Davis BM, Rall GF, Schnell MJ. Everything You Always Wanted to Know About Rabies Virus (But Were Afraid to Ask). Annu Rev Virol. 2015 Nov; 2(1):451-71. PMID: 26958924.
      View in: PubMed
    28. Willet M, Kurup D, Papaneri A, Wirblich C, Hooper JW, Kwilas SA, Keshwara R, Hudacek A, Beilfuss S, Rudolph G, Pommerening E, Vos A, Neubert A, Jahrling P, Blaney JE, Johnson RF, Schnell MJ. Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and Filoviruses. J Infect Dis. 2015 Oct 1; 212 Suppl 2:S414-24. PMID: 26063224.
      View in: PubMed
    29. Pfaller CK, Cattaneo R, Schnell MJ. Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeutics. Virology. 2015 May; 479-480:331-44. PMID: 25702088.
      View in: PubMed
    30. Papaneri AB, Bernbaum JG, Blaney JE, Jahrling PB, Schnell MJ, Johnson RF. Controlled viral glycoprotein expression as a safety feature in a bivalent rabies-ebola vaccine. Virus Res. 2015 Feb 2; 197:54-8. PMID: 25481284.
      View in: PubMed
    31. Kurup D, Wirblich C, Feldmann H, Marzi A, Schnell MJ. Rhabdovirus-Based Vaccine Platforms against Henipaviruses. J Virol. 2015 Jan 1; 89(1):144-54. PMID: 25320306.
      View in: PubMed
    32. Hudacek AW, Al-Saleem FH, Willet M, Eisemann T, Mattis JA, Simpson LL, Schnell MJ. Recombinant rabies virus particles presenting botulinum neurotoxin antigens elicit a protective humoral response in vivo. Mol Ther Methods Clin Dev. 2014; 1:14046. PMID: 26015984.
      View in: PubMed
    33. Han Z, Lu J, Liu Y, Davis B, Lee MS, Olson MA, Ruthel G, Freedman BD, Schnell MJ, Wrobel JE, Reitz AB, Harty RN. Small-Molecule Probes Targeting the Viral PPxY-Host Nedd4 Interface Block Egress of a Broad Range of RNA Viruses. J Virol. 2014 Jul 1; 88(13):7294-306. PMID: 24741084.
      View in: PubMed
    34. McGettigan JP, David F, Figueiredo MD, Minke J, Mebatsion T, Schnell MJ. Safety and serological response to a matrix gene-deleted rabies virus-based vaccine vector in dogs. Vaccine. 2014 Mar 26; 32(15):1716-9. PMID: 24508037.
      View in: PubMed
    35. Papaneri AB, Wirblich C, Marissen WE, Schnell MJ. Alanine scanning of the rabies virus glycoprotein antigenic site III using recombinant rabies virus: Implication for post-exposure treatment. Vaccine. 2013 Dec 2; 31(49):5897-902. PMID: 24120673.
      View in: PubMed
    36. Lawrence TM, Wanjalla CN, Gomme EA, Wirblich C, Gatt A, Carnero E, García-Sastre A, Lyles DS, McGettigan JP, Schnell MJ. Comparison of Heterologous Prime-Boost Strategies against Human Immunodeficiency Virus Type 1 Gag Using Negative Stranded RNA Viruses. PLoS One. 2013; 8(6):e67123. PMID: 23840600.
      View in: PubMed
    37. Blaney JE, Marzi A, Willet M, Papaneri AB, Wirblich C, Feldmann F, Holbrook M, Jahrling P, Feldmann H, Schnell MJ. Antibody quality and protection from lethal ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine. PLoS Pathog. 2013 May; 9(5):e1003389. PMID: 23737747.
      View in: PubMed
    38. Lawrence TM, Hudacek AW, de Zoete MR, Flavell RA, Schnell MJ. Rabies Virus Is Recognized by the NLRP3 Inflammasome and Activates Interleukin-1ß Release in Murine Dendritic Cells. J Virol. 2013 May; 87(10):5848-57. PMID: 23487464.
      View in: PubMed
    39. Marston DA, McElhinney LM, Banyard AC, Horton DL, Núñez A, Koser ML, Schnell MJ, Fooks AR. Interspecies protein substitution to investigate the role of the lyssavirus glycoprotein. J Gen Virol. 2013 Feb; 94(Pt 2):284-92. PMID: 23100360.
      View in: PubMed
    40. Gomme EA, Wirblich C, Addya S, Rall GF, Schnell MJ. Immune clearance of attenuated rabies virus results in neuronal survival with altered gene expression. PLoS Pathog. 2012 Oct; 8(10):e1002971. PMID: 23071441.
      View in: PubMed
    41. Papaneri AB, Wirblich C, Cann JA, Cooper K, Jahrling PB, Schnell MJ, Blaney JE. A replication-deficient rabies virus vaccine expressing Ebola virus glycoprotein is highly attenuated for neurovirulence. Virology. 2012 Dec 5; 434(1):18-26. PMID: 22889613.
      View in: PubMed
    42. Papaneri AB, Wirblich C, Cooper K, Jahrling PB, Schnell MJ, Blaney JE. Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein. Vaccine. 2012 Sep 21; 30(43):6136-41. PMID: 22884661.
      View in: PubMed
    43. Nguyen TD, Wirblich C, Aizenman E, Schnell MJ, Strick PL, Kandler K. Targeted single-neuron infection with rabies virus for transneuronal multisynaptic tracing. J Neurosci Methods. 2012 Aug 15; 209(2):367-70. PMID: 22749814.
      View in: PubMed
    44. Nunnari G, Coco C, Pinzone MR, Pavone P, Berretta M, Di Rosa M, Schnell M, Calabrese G, Cacopardo B. The role of micronutrients in the diet of HIV-1-infected individuals. Front Biosci (Elite Ed). 2012; 4:2442-56. PMID: 22652651.
      View in: PubMed
    45. Wanjalla CN, Goldstein EF, Wirblich C, Schnell MJ. A role for granulocyte-macrophage colony-stimulating factor in the regulation of CD8(+) T cell responses to rabies virus. Virology. 2012 May 10; 426(2):120-33. PMID: 22341782.
      View in: PubMed
    46. Liang Z, Diamond M, Smith JA, Schnell M, Daniel R. Proliferating cell nuclear antigen is required for loading of the SMCX/KMD5C histone demethylase onto chromatin. Epigenetics Chromatin. 2011; 4(1):18. PMID: 21996408.
      View in: PubMed
    47. Blaney JE, Wirblich C, Papaneri AB, Johnson RF, Myers CJ, Juelich TL, Holbrook MR, Freiberg AN, Bernbaum JG, Jahrling PB, Paragas J, Schnell MJ. Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. J Virol. 2011 Oct; 85(20):10605-16. PMID: 21849459.
      View in: PubMed
    48. Nunnari G, Schnell MJ. MicroRNA-122: a therapeutic target for hepatitis C virus (HCV) infection. Front Biosci (Schol Ed). 2011; 3:1032-7. PMID: 21622252.
      View in: PubMed
    49. Mustafa W, Al-Saleem FH, Nasser Z, Olson RM, Mattis JA, Simpson LL, Schnell MJ. Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge. Vaccine. 2011 Jun 20; 29(28):4638-45. PMID: 21549784.
      View in: PubMed
    50. Gomme EA, Wanjalla CN, Wirblich C, Schnell MJ. Rabies virus as a research tool and viral vaccine vector. Adv Virus Res. 2011; 79:139-64. PMID: 21601047.
      View in: PubMed
    51. Wirblich C, Schnell MJ. Rabies virus (RV) glycoprotein expression levels are not critical for pathogenicity of RV. J Virol. 2011 Jan; 85(2):697-704. PMID: 21068252.
      View in: PubMed
    52. Wanjalla CN, Faul EJ, Gomme EA, Schnell MJ. Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity. Vaccine. 2010 Dec 10; 29(1):130-40. PMID: 20728525.
      View in: PubMed
    53. Faul EJ, Wanjalla CN, Suthar MS, Gale M, Wirblich C, Schnell MJ. Rabies virus infection induces type I interferon production in an IPS-1 dependent manner while dendritic cell activation relies on IFNAR signaling. PLoS Pathog. 2010; 6(7):e1001016. PMID: 20661430.
      View in: PubMed
    54. Langley WA, Bradley KC, Li ZN, Smith ME, Schnell MJ, Steinhauer DA. Induction of neutralizing antibody responses to anthrax protective antigen by using influenza virus vectors: implications for disparate immune system priming pathways. J Virol. 2010 Aug; 84(16):8300-7. PMID: 20504926.
      View in: PubMed
    55. Préhaud C, Wolff N, Terrien E, Lafage M, Mégret F, Babault N, Cordier F, Tan GS, Maitrepierre E, Ménager P, Chopy D, Hoos S, England P, Delepierre M, Schnell MJ, Buc H, Lafon M. Attenuation of rabies virulence: takeover by the cytoplasmic domain of its envelope protein. Sci Signal. 2010; 3(105):ra5. PMID: 20086240.
      View in: PubMed
    56. Gomme EA, Faul EJ, Flomenberg P, McGettigan JP, Schnell MJ. Characterization of a single-cycle rabies virus-based vaccine vector. J Virol. 2010 Mar; 84(6):2820-31. PMID: 20053743.
      View in: PubMed
    57. Schnell MJ, McGettigan JP, Wirblich C, Papaneri A. The cell biology of rabies virus: using stealth to reach the brain. Nat Rev Microbiol. 2010 Jan; 8(1):51-61. PMID: 19946287.
      View in: PubMed
    58. Mareeva T, Wanjalla C, Schnell MJ, Sykulev Y. A novel composite immunotoxin that suppresses rabies virus production by the infected cells. J Immunol Methods. 2010 Feb 28; 353(1-2):78-86. PMID: 19932697.
      View in: PubMed
    59. Faul EJ, Lyles DS, Schnell MJ. Interferon response and viral evasion by members of the family rhabdoviridae. Viruses. 2009 Dec; 1(3):832-51. PMID: 21994572.
      View in: PubMed
    60. Faul EJ, Aye PP, Papaneri AB, Pahar B, McGettigan JP, Schiro F, Chervoneva I, Montefiori DC, Lackner AA, Schnell MJ. Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus macaques from AIDS-like disease after SIV(mac251) challenge. Vaccine. 2009 Dec 11; 28(2):299-308. PMID: 19879223.
      View in: PubMed
    61. Cenna J, Hunter M, Tan GS, Papaneri AB, Ribka EP, Schnell MJ, Marx PA, McGettigan JP. Replication-deficient rabies virus-based vaccines are safe and immunogenic in mice and nonhuman primates. J Infect Dis. 2009 Oct 15; 200(8):1251-60. PMID: 19764884.
      View in: PubMed
    62. Preuss MA, Faber ML, Tan GS, Bette M, Dietzschold B, Weihe E, Schnell MJ. Intravenous inoculation of a bat-associated rabies virus causes lethal encephalopathy in mice through invasion of the brain via neurosecretory hypothalamic fibers. PLoS Pathog. 2009 Jun; 5(6):e1000485. PMID: 19543379.
      View in: PubMed
    63. Snook AE, Li P, Stafford BJ, Faul EJ, Huang L, Birbe RC, Bombonati A, Schulz S, Schnell MJ, Eisenlohr LC, Waldman SA. Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease. Cancer Res. 2009 Apr 15; 69(8):3537-44. PMID: 19351847.
      View in: PubMed
    64. Faul EJ, Wanjalla CN, McGettigan JP, Schnell MJ. Interferon-beta expressed by a rabies virus-based HIV-1 vaccine vector serves as a molecular adjuvant and decreases pathogenicity. Virology. 2008 Dec 20; 382(2):226-38. PMID: 18945463.
      View in: PubMed
    65. Cenna J, Tan GS, Papaneri AB, Dietzschold B, Schnell MJ, McGettigan JP. Immune modulating effect by a phosphoprotein-deleted rabies virus vaccine vector expressing two copies of the rabies virus glycoprotein gene. Vaccine. 2008 Nov 25; 26(50):6405-14. PMID: 18804506.
      View in: PubMed
    66. Dietzschold B, Li J, Faber M, Schnell M. Concepts in the pathogenesis of rabies. Future Virol. 2008 Sep; 3(5):481-490. PMID: 19578477.
      View in: PubMed
    67. Wirblich C, Tan GS, Papaneri A, Godlewski PJ, Orenstein JM, Harty RN, Schnell MJ. PPEY motif within the rabies virus (RV) matrix protein is essential for efficient virion release and RV pathogenicity. J Virol. 2008 Oct; 82(19):9730-8. PMID: 18667490.
      View in: PubMed
    68. Snook AE, Stafford BJ, Li P, Tan G, Huang L, Birbe R, Schulz S, Schnell MJ, Thakur M, Rothstein JL, Eisenlohr LC, Waldman SA. Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity. J Natl Cancer Inst. 2008 Jul 2; 100(13):950-61. PMID: 18577748.
      View in: PubMed
    69. Pulmanausahakul R, Li J, Schnell MJ, Dietzschold B. The glycoprotein and the matrix protein of rabies virus affect pathogenicity by regulating viral replication and facilitating cell-to-cell spread. J Virol. 2008 Mar; 82(5):2330-8. PMID: 18094173.
      View in: PubMed
    70. Li J, McGettigan JP, Faber M, Schnell MJ, Dietzschold B. Infection of monocytes or immature dendritic cells (DCs) with an attenuated rabies virus results in DC maturation and a strong activation of the NFkappaB signaling pathway. Vaccine. 2008 Jan 17; 26(3):419-26. PMID: 18082293.
      View in: PubMed
    71. Faber M, Faber ML, Li J, Preuss MA, Schnell MJ, Dietzschold B. Dominance of a nonpathogenic glycoprotein gene over a pathogenic glycoprotein gene in rabies virus. J Virol. 2007 Jul; 81(13):7041-7. PMID: 17459937.
      View in: PubMed
    72. Tan GS, Preuss MA, Williams JC, Schnell MJ. The dynein light chain 8 binding motif of rabies virus phosphoprotein promotes efficient viral transcription. Proc Natl Acad Sci U S A. 2007 Apr 24; 104(17):7229-34. PMID: 17438267.
      View in: PubMed
    73. McKenna PM, Koser ML, Carlson KR, Montefiori DC, Letvin NL, Papaneri AB, Pomerantz RJ, Dietzschold B, Silvera P, McGettigan JP, Schnell MJ. Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease. J Infect Dis. 2007 Apr 1; 195(7):980-8. PMID: 17330788.
      View in: PubMed
    74. Tang J, Murtadha M, Schnell M, Eisenlohr LC, Hooper J, Flomenberg P. Human T-cell responses to vaccinia virus envelope proteins. J Virol. 2006 Oct; 80(20):10010-20. PMID: 17005679.
      View in: PubMed
    75. Li J, Faber M, Papaneri A, Faber ML, McGettigan JP, Schnell MJ, Dietzschold B. A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice. Virology. 2006 Dec 5-20; 356(1-2):147-54. PMID: 16938327.
      View in: PubMed
    76. Smith ME, Koser M, Xiao S, Siler C, McGettigan JP, Calkins C, Pomerantz RJ, Dietzschold B, Schnell MJ. Rabies virus glycoprotein as a carrier for anthrax protective antigen. Virology. 2006 Sep 30; 353(2):344-56. PMID: 16820183.
      View in: PubMed
    77. Plesa G, McKenna PM, Schnell MJ, Eisenlohr LC. Immunogenicity of cytopathic and noncytopathic viral vectors. J Virol. 2006 Jul; 80(13):6259-66. PMID: 16775313.
      View in: PubMed
    78. Tang J, Olive M, Pulmanausahakul R, Schnell M, Flomenberg N, Eisenlohr L, Flomenberg P. Human CD8+ cytotoxic T cell responses to adenovirus capsid proteins. Virology. 2006 Jul 5; 350(2):312-22. PMID: 16499941.
      View in: PubMed
    79. Dave RS, McGettigan JP, Qureshi T, Schnell MJ, Nunnari G, Pomerantz RJ. siRNA targeting vaccinia virus double-stranded RNA binding protein [E3L] exerts potent antiviral effects. Virology. 2006 May 10; 348(2):489-97. PMID: 16480752.
      View in: PubMed
    80. Faber M, Bette M, Preuss MA, Pulmanausahakul R, Rehnelt J, Schnell MJ, Dietzschold B, Weihe E. Overexpression of tumor necrosis factor alpha by a recombinant rabies virus attenuates replication in neurons and prevents lethal infection in mice. J Virol. 2005 Dec; 79(24):15405-16. PMID: 16306612.
      View in: PubMed
    81. Faber M, Faber ML, Papaneri A, Bette M, Weihe E, Dietzschold B, Schnell MJ. A single amino acid change in rabies virus glycoprotein increases virus spread and enhances virus pathogenicity. J Virol. 2005 Nov; 79(22):14141-8. PMID: 16254349.
      View in: PubMed
    82. McGettigan JP, Koser ML, McKenna PM, Smith ME, Marvin JM, Eisenlohr LC, Dietzschold B, Schnell MJ. Enhanced humoral HIV-1-specific immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2. Virology. 2006 Jan 20; 344(2):363-77. PMID: 16226782.
      View in: PubMed
    83. Faber M, Lamirande EW, Roberts A, Rice AB, Koprowski H, Dietzschold B, Schnell MJ. A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies. J Gen Virol. 2005 May; 86(Pt 5):1435-40. PMID: 15831955.
      View in: PubMed
    84. Schnell MJ, Tan GS, Dietzschold B. The application of reverse genetics technology in the study of rabies virus (RV) pathogenesis and for the development of novel RV vaccines. J Neurovirol. 2005 Feb; 11(1):76-81. PMID: 15804964.
      View in: PubMed
    85. Tan GS, McKenna PM, Koser ML, McLinden R, Kim JH, McGettigan JP, Schnell MJ. Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach. Virology. 2005 Jan 5; 331(1):82-93. PMID: 15582655.
      View in: PubMed
    86. Dietzschold ML, Faber M, Mattis JA, Pak KY, Schnell MJ, Dietzschold B. In vitro growth and stability of recombinant rabies viruses designed for vaccination of wildlife. Vaccine. 2004 Dec 9; 23(4):518-24. PMID: 15530701.
      View in: PubMed
    87. McKenna PM, Aye PP, Dietzschold B, Montefiori DC, Martin LN, Marx PA, Pomerantz RJ, Lackner A, Schnell MJ. Immunogenicity study of glycoprotein-deficient rabies virus expressing simian/human immunodeficiency virus SHIV89.6P envelope in a rhesus macaque. J Virol. 2004 Dec; 78(24):13455-9. PMID: 15564456.
      View in: PubMed
    88. Faber M, Pulmanausahakul R, Nagao K, Prosniak M, Rice AB, Koprowski H, Schnell MJ, Dietzschold B. Identification of viral genomic elements responsible for rabies virus neuroinvasiveness. Proc Natl Acad Sci U S A. 2004 Nov 16; 101(46):16328-32. PMID: 15520387.
      View in: PubMed
    89. Koser ML, McGettigan JP, Tan GS, Smith ME, Koprowski H, Dietzschold B, Schnell MJ. Rabies virus nucleoprotein as a carrier for foreign antigens. Proc Natl Acad Sci U S A. 2004 Jun 22; 101(25):9405-10. PMID: 15197258.
      View in: PubMed
    90. Goodrich A, Parveen Z, Dornburg R, Schnell MJ, Pomerantz RJ. Spliced spleen necrosis virus vector RNA is not encapsidated: implications for retroviral replication and vector design. Mol Ther. 2004 Apr; 9(4):557-65. PMID: 15093186.
      View in: PubMed
    91. Irie T, Licata JM, McGettigan JP, Schnell MJ, Harty RN. Budding of PPxY-containing rhabdoviruses is not dependent on host proteins TGS101 and VPS4A. J Virol. 2004 Mar; 78(6):2657-65. PMID: 14990685.
      View in: PubMed
    92. McKenna PM, Pomerantz RJ, Dietzschold B, McGettigan JP, Schnell MJ. Covalently linked human immunodeficiency virus type 1 gp120/gp41 is stably anchored in rhabdovirus particles and exposes critical neutralizing epitopes. J Virol. 2003 Dec; 77(23):12782-94. PMID: 14610200.
      View in: PubMed
    93. McGettigan JP, Naper K, Orenstein J, Koser M, McKenna PM, Schnell MJ. Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome. J Virol. 2003 Oct; 77(20):10889-99. PMID: 14512539.
      View in: PubMed
    94. Parveen Z, Mukhtar M, Rafi M, Wenger DA, Siddiqui KM, Siler CA, Dietzschold B, Pomerantz RJ, Schnell MJ, Dornburg R. Cell-type-specific gene delivery into neuronal cells in vitro and in vivo. Virology. 2003 Sep 15; 314(1):74-83. PMID: 14517061.
      View in: PubMed
    95. Dietzschold B, Faber M, Schnell MJ. New approaches to the prevention and eradication of rabies. Expert Rev Vaccines. 2003 Jun; 2(3):399-406. PMID: 12903805.
      View in: PubMed
    96. McKenna PM, McGettigan JP, Pomerantz RJ, Dietzschold B, Schnell MJ. Recombinant rhabdoviruses as potential vaccines for HIV-1 and other diseases. Curr HIV Res. 2003 Apr; 1(2):229-37. PMID: 15043205.
      View in: PubMed
    97. McGettigan JP, Pomerantz RJ, Siler CA, McKenna PM, Foley HD, Dietzschold B, Schnell MJ. Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic. J Virol. 2003 Jan; 77(1):237-44. PMID: 12477829.
      View in: PubMed
    98. McGettigan JP, McKenna PM, Schnell MJ. HIV-1 vaccines: the search continues. Clin Lab Med. 2002 Sep; 22(3):799-820, viii. PMID: 12244598.
      View in: PubMed
    99. Wu X, Gong X, Foley HD, Schnell MJ, Fu ZF. Both viral transcription and replication are reduced when the rabies virus nucleoprotein is not phosphorylated. J Virol. 2002 May; 76(9):4153-61. PMID: 11932380.
      View in: PubMed
    100. Dietzschold B, Schnell MJ. New approaches to the development of live attenuated rabies vaccines. Hybrid Hybridomics. 2002 Apr; 21(2):129-34. PMID: 12031103.
      View in: PubMed
    101. Faber M, Pulmanausahakul R, Hodawadekar SS, Spitsin S, McGettigan JP, Schnell MJ, Dietzschold B. Overexpression of the rabies virus glycoprotein results in enhancement of apoptosis and antiviral immune response. J Virol. 2002 Apr; 76(7):3374-81. PMID: 11884563.
      View in: PubMed
    102. Siler CA, McGettigan JP, Dietzschold B, Herrine SK, Dubuisson J, Pomerantz RJ, Schnell MJ. Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines. Virology. 2002 Jan 5; 292(1):24-34. PMID: 11878905.
      View in: PubMed
    103. Foley HD, Otero M, Orenstein JM, Pomerantz RJ, Schnell MJ. Rhabdovirus-based vectors with human immunodeficiency virus type 1 (HIV-1) envelopes display HIV-1-like tropism and target human dendritic cells. J Virol. 2002 Jan; 76(1):19-31. PMID: 11739668.
      View in: PubMed
    Schnell's Networks
    Click the "See All" links for more information and interactive visualizations!
    Same Department Expand Description